Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

• Pierre Fenaux, Ghulam J. Mufti, +16 authors Lewis R. Silverman
• The Lancet. Oncology
• 2009

BACKGROUND Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival… (More)

Revised international prognostic scoring system for myelodysplastic syndromes.

• Peter L. Greenberg, Heinz Tuechler, +31 authors Detlef Haase
• Blood
• 2012

The International Prognostic Scoring System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS… (More)

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

• Bruce D Cheson, Peter L. Greenberg, +12 authors Hagop Kantarjian
• Blood
• 2006

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating… (More)

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

• Bruce D Cheson, J. Michael Bennett, +12 authors Peter L. Greenberg
• Blood
• 2000

Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of… (More)

Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

• Vanderson Rocha, Myriam Labopin, +9 authors Eliane Gluckman
• The New England journal of medicine
• 2004

BACKGROUND Promising results of cord-blood transplants from unrelated donors have been reported in adults. METHODS We compared outcomes in 682 adults with acute leukemia who received a… (More)

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

• Pierre Fenaux, Ghulam J. Mufti, +13 authors Lewis R. Silverman
• Journal of clinical oncology : official journal…
• 2010

PURPOSE In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk… (More)

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

• Pierre Fenaux, Aristoteles Achilles Nikolaus Giagounidis, +21 authors Eva Hellström-Lindberg
• Blood
• 2011

This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System… (More)

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

• Leonie Saft, Mohsen Karimi, +16 authors Eva Hellström-Lindberg
• Haematologica
• 2014

Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermediate-1-risk (lower-risk) are considered to have an indolent course; however, recent data… (More)

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.

• Guillermo Sanz, M. A. Sanz Sanz, +5 authors Jesús Fernando San Miguel
• Blood
• 1989

Therapy planning in patients with myelodysplastic syndromes (MDSs) is complicated by its high prognostic heterogeneity. Forty-one patient and disease characteristics at onset of 370 patients with MDS… (More)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

• Aristoteles Achilles Nikolaus Giagounidis, Pierre Fenaux, +6 authors Richard A. Wells
• Annals of Hematology
• 2008

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›